A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)

NCT04995484 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate Hepatic Impairment

Interventions

DRUG: Belzutifan

Sponsor

Merck Sharp & Dohme LLC